TECHNICAL FIELD

The present disclosure relates to a composition for cell protection that includes cyclo histidine-proline (Cyclo His-Pro, CHP) as an active ingredient.

BACKGROUND ART

Cyclo histidine-proline (Cyclo His-Pro, CHP) is a naturally-generating cyclic dipeptide that is structurally related to thyrotropin-releasing hormone (TRH). The cyclo histidine-proline (CHP) is a peptide inherent in animal and human tissues and body fluids. The CHP is found in blood, semen, gastrointestinal tract, urine, etc., and in particular is a metabolite rich in prostate. The cyclo histidine-proline (CHP) has been known to have a variety of physiological functions such as anti-diabetes, anti-obesity, anti-inflammatory and antioxidant effects.

Apoptosis is an important process in the normal development and function of multicellular organisms. Physiological apoptosis plays an important role in normal processes, but abnormal apoptosis causes various diseases. For example, inhibition of apoptosis may lead to cancer, autoimmune diseases, inflammatory diseases, and viral infections.

Further, the apoptosis is known to be associated with degenerative neurological diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Lou Gehrig's disease, and acute diseases such as cerebral ischemia, traumatic brain injury, spinal cord injury, and stroke.

However, there has been no report on the cytoprotective effect of the cyclo histidine-proline (CHP) and its mechanism.

DISCLOSURE

Technical Problem

The present inventors have experimentally confirmed that the cyclohistidine-proline (CHP) inhibits apoptosis of kidney cells and liver cells induced by high-level drug treatment and protects cells, thereby to complete the present disclosure.

One purpose of the present disclosure is to provide a cell-protecting pharmaceutical composition including the cyclo histidine-proline (CHP) or a pharmaceutically acceptable salt thereof as an active ingredient.

Another purpose of the present disclosure is to provide a health functional food for preventing or ameliorating liver or kidney damage, the food including the cyclo histidine-proline (CHP) or a food acceptable salt thereof as an active ingredient.

Technical Solution

To this end, the present disclosure provides a cell-protecting pharmaceutical composition including the cyclo histidine-proline (CHP) or a pharmaceutically acceptable salt thereof as an active ingredient.

According to an embodiment of the present disclosure, the cell may be a kidney cell or a liver cell.

According to an embodiment of the present disclosure, the composition may inhibit apoptosis.

According to an embodiment of the present disclosure, the composition may inhibit drug-induced cellular damage.

According to an embodiment of the present disclosure, the drug may be an anticancer agent or an antibiotic agent, in which the anticancer agent may be one or more platinum-based anticancer agents selected from a group consisting of cisplatin, carboplatin, oxaliplatin and nedaplatin.

Further, the present disclosure provides a health functional food for preventing or ameliorating liver or kidney damage, the food including the cyclo histidine-proline (CHP) or a food acceptable salt thereof as an active ingredient.

According to an embodiment of the present disclosure, a drug inducing the liver or kidney toxicity or damage may be one or more anticancer agents or antibiotic agents selected from a group consisting of cisplatin, gentamycin (GM) and acetaminophen (APAP).

Advantageous Effects

According to the present disclosure, the cell-protecting pharmaceutical composition including the cyclo histidine-proline (Cyclo His-Pro, CHP) as an active ingredient may inhibit the apoptosis of kidney cells or liver cells caused by toxicity. Thus, the composition may be useful as a composition for preventing and treating kidney and liver toxicity.

